The role of SARS‐CoV‐2 infection and its vaccines in various types of hair loss

Aryanian, Zeinab; Balighi, Kamran; Hatami, Parvaneh; Afshar, Zeinab Mohseni; Mohandesi, Nessa Aghazadeh

doi:10.1111/dth.15433

Cited by 19 publications

(21 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many case reports and studies of hair involvement reported after COVID‐19 vaccination have been published in the literature. 35 , 36 , 37 Nonetheless, since our study focused on cutaneous reactions, hair involvement after COVID‐19 vaccination was not examined separately. However, the current study also had several strengths, such as more than 95% of non‐local cutaneous reactions being diagnosed by a dermatologist and the participants being questioned through one‐to‐one interviews.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous reactions after COVID‐19 vaccination in Turkey: A multicenter study

Cebeci

Erdoğan

Aktaş

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Objectives In this study covering all of Turkey, we aimed to define cutaneous and systemic adverse reactions in our patient population after COVID‐19 vaccination with the Sinovac/CoronaVac (inactivated SARS‐CoV‐2) and Pfizer/BioNTech (BNT162b2) vaccines. Methods This prospective, cross‐sectional study included individuals presenting to the dermatology or emergency outpatient clinics of a total of 19 centers after having been vaccinated with the COVID‐19 vaccines. Systemic, local injection site, and non‐local cutaneous reactions after vaccination were identified, and their rates were determined. Results Of the 2290 individuals vaccinated between April 15 and July 15, 2021, 2097 (91.6%) received the CoronaVac vaccine and 183 (8%) BioNTech. Systemic reactions were observed at a rate of 31.0% after the first CoronaVac dose, 31.1% after the second CoronaVac dose, 46.4% after the first BioNTech dose, and 46.2% after the second BioNTech dose. Local injection site reactions were detected at a rate of 35.6% after the first CoronaVac dose, 35.7% after the second CoronaVac dose, 86.9% after the first BioNTech dose, and 94.1% after the second BioNTech dose. A total of 133 non‐local cutaneous reactions were identified after the CoronaVac vaccine (2.9% after the first dose and 3.5% after the second dose), with the most common being urticaria/angioedema, pityriasis rosea, herpes zoster, and maculopapular rash. After BioNTech, 39 non‐local cutaneous reactions were observed to have developed (24.8% after the first dose and 5% after the second dose), and the most common were herpes zoster, delayed large local reaction, pityriasis rosea, and urticaria/angioedema in order of frequency. Existing autoimmune diseases were triggered in 2.1% of the patients vaccinated with CoronaVac and 8.2% of those vaccinated with BioNTech. Conclusions There are no comprehensive data on cutaneous adverse reactions specific to the CoronaVac vaccine. We determined the frequency of adverse reactions from the dermatologist's point of view after CoronaVac and BioNTech vaccination and identified a wide spectrum of non‐local cutaneous reactions. Our data show that CoronaVac is associated with less harmful reactions while BioNTech may result in more serious reactions, such as herpes zoster, anaphylaxis, and triggering of autoimmunity. However, most of these reactions were self‐limiting or required little therapeutic intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

Cutaneous reactions after COVID‐19 vaccination in Turkey: A multicenter study

Cebeci

Erdoğan

Aktaş

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…AA is an autoimmune-mediated hair loss with an estimated incidence of around 2% in the community [8]. Genetic factors, autoimmune diseases, stress, atopic diathesis, nutritional deficiency, hormonal changes, infections, and vaccination have been implicated in the pathogenesis of this disease.…”

Section: Discussionmentioning

confidence: 99%

“…Cases of AA have been identified after vaccination against influenza virus, hepatitis B virus, herpes zoster virus, human papillomavirus, Japanese encephalitis, and Clostridium tetani [6,7]. During this pandemic, acute SARS-CoV-2 infection has been associated with the development of telogen effluvium, alopecia areata, friction alopecia, and anagen effluvium [8]. AA following various SARS-CoV-2 vaccine injections was rarely reported, however [1,6,7,[9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Diffuse Alopecia Areata and Its Trichoscopic Findings Following COVID-19 mRNA-1273 Vaccination: A Case Report

Chen¹

2022

JDR

View full text Add to dashboard Cite

Background: Alopecia Areata (AA) is a common autoimmune disease leading to non-scarring hair loss. Previously, AA had been noted following various vaccinations including influenza virus, hepatitis B virus, herpes zoster virus, human papillomavirus, Japanese encephalitis, and Clostridium tetani. During this pandemic, AA following SARS-CoV-2 vaccine injection was rarely reported Objective: We report a case of diffuse AA and its trichoscopic findings following COVID-19 mRNA-1273 vaccination. Method: A trichoscopic examination of the scalp was performed. An English literature review through PubMed and an online search of the Vaccine Adverse Event Reporting System (VAERS) database were conducted. Finding: Only 20 patients of AA following SARS-CoV-2 vaccination were reported in the English literature. Black dots and broken hair were the most common features, followed by yellow dots and exclamation mark hairs. The VAERS database showed 77.8% were associated with the BNT162b2 vaccine and 20.9% with the COVID-19 mRNA-1273 vaccine, respectively. Conclusion: A rare case of AA and its trichoscopic findings following COVID-19 mRNA-1273 vaccine injection was reported. The COVID-19 vaccines may play a role in various immune-related dermatologic conditions.

show abstract

“…Several types of hair loss have been reported after COVID-19 vaccination, including alopecia areata and telogen effluvium [ 117 – 121 ]. Alopecia areata has been noted either with rapid onset after vaccination or recurrences of alopecia areata after COVID-19 vaccination [ 117 – 122 ].…”

Section: Cutaneous Reactions To Covid-19 Vaccinesmentioning

confidence: 99%

Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin

Singh

Freeman

2022

Curr Derm Rep

View full text Add to dashboard Cite

Purpose of Review This review aims to evaluate the spectrum of cutaneous reactions after both SARS-CoV-2 infection and COVID-19 vaccination while simultaneously understanding the evolution of the field of dermatology in the face of an ongoing pandemic. Recent Findings The most commonly reported cutaneous reactions after COVID-19 infection in the literature to date include morbilliform or maculopapular rashes, chilblains, and urticaria. The incidence of cutaneous reactions after COVID-19 vaccination was 9% in larger cohort studies and more commonly occurred after mRNA-based COVID-19 vaccines than adenovirus vector vaccines. The most frequently reported cutaneous reactions after COVID-19 vaccines were delayed large local reactions, local injection site reactions, urticarial eruptions, and morbilliform eruptions. Summary With the ongoing pandemic, and continued development of new COVID-19 variants and vaccines, the landscape of cutaneous reactions continues to rapidly evolve. Dermatologists have an important role in evaluating skin manifestations of the virus, as well as discussion and promoting COVID-19 vaccination for their patients.

show abstract

The role of SARS‐CoV‐2 infection and its vaccines in various types of hair loss

Cited by 19 publications

References 54 publications

Cutaneous reactions after COVID‐19 vaccination in Turkey: A multicenter study

Cutaneous reactions after COVID‐19 vaccination in Turkey: A multicenter study

Diffuse Alopecia Areata and Its Trichoscopic Findings Following COVID-19 mRNA-1273 Vaccination: A Case Report

Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin

Contact Info

Product

Resources

About